Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03330691 · ClinicalTrials.gov registry record · Phase 1
A Feasibility and Safety Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Leukemia
A Phase 1 study of Lymphoma and Leukemia, sponsored by Seattle Children's Hospital.
- Active
- Registry status
- Phase 1
- Development phase
- 78
- Enrollment target
- 5
- Study locations
NCT03330691 is a Phase 1 study of Lymphoma and Leukemia that is active but no longer recruiting, run by Seattle Children's Hospital. The registered enrollment target is 78 participants, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (84% lower). The trial reports 5 study locations across 5 states.
The verdict
NCT03330691, a Phase 1 study of Lymphoma and Leukemia, is active but no longer recruiting, sponsored by Seattle Children's Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 78 participants
- Enrollment target
- 5
- Study locations
Study Summary
Patients with relapsed or refractory leukemia often develop resistance to chemotherapy and some patients who relapse following CD19 directed therapy relapse with CD19 negative leukemia. For this reason, the investigators are attempting to use T-cells obtained directly from the patient, which can be genetically modified to express two chimeric antigen receptors (CARs). One is to recognize CD19 and the other is to recognize CD22, both of which are proteins expressed on the surface of the leukemic cell in patients with CD19+CD22+ leukemia. The CAR enables the T-cell to recognize and kill the leukemic cell through recognition of CD19 and CD22. This is a phase 1 study designed to determine the safety of the CAR+ T-cells and the feasibility of making enough to treat patients with CD19+CD22+ leukemia.
Interventions
- BIOLOGICAL Patient-derived CD19- and CD22 specific CAR
Study Locations (5)
California
- Children's Hospital Los Angeles - Los Angeles
District of Columbia
- Children's National Medical Center - Washington D.C.
Indiana
- Riley Hospital for Children - Indianapolis
Washington
- Seattle Children's Hospital - Seattle
British Columbia
- Children's and Women's Health Centre of British Columbia - Vancouver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2017-11-03 |
| Est. Completion | 2035-03-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03330691
The ClinicalTrials.gov registry entry for NCT03330691 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (84% lower). The listed sponsor is Seattle Children's Hospital, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which Patient-derived CD19- and CD22 specific CAR is the first listed.
NCT03330691 reports 5 study locations spanning 5 distinct geographic areas - top geographies include California, District of Columbia, Indiana.
Frequently Asked Questions
What is clinical trial NCT03330691 about?
NCT03330691 is a clinical study titled "A Feasibility and Safety Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Leukemia". Patients with relapsed or refractory leukemia often develop resistance to chemotherapy and some patients who relapse following CD19 directed therapy relapse with CD19 negative leukemia. For this reason, the investigators are attempting to use T-cells obtained directly from the patient, which can be ...
What is the current status of trial NCT03330691?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 78 participants. The study started on 2017-11-03. Estimated completion is 2035-03-03.
What conditions does trial NCT03330691 study?
This clinical trial studies the following conditions: Lymphoma, Leukemia.
What interventions are being tested in trial NCT03330691?
The interventions under investigation include: Patient-derived CD19- and CD22 specific CAR (BIOLOGICAL).
Who is sponsoring clinical trial NCT03330691?
This trial is sponsored by Seattle Children's Hospital, which has 168 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03330691 being conducted?
This trial has 5 study locations across California, District of Columbia, Indiana, Washington, British Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma
RECRUITING · Phase 1
-
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
RECRUITING · Phase 1
-
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
RECRUITING · Phase 1
-
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
RECRUITING · Phase 1
-
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
RECRUITING · Phase 1
-
A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.